Your browser doesn't support javascript.
loading
Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis.
Tian, Bao-Wen; Yang, Ya-Fei; Yang, Chun-Cheng; Yan, Lun-Jie; Ding, Zi-Niu; Liu, Hui; Xue, Jun-Shuai; Dong, Zhao-Ru; Chen, Zhi-Qiang; Hong, Jian-Guo; Wang, Dong-Xu; Han, Cheng-Long; Mao, Xin-Cheng; Li, Tao.
Affiliation
  • Tian BW; Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China.
  • Yang YF; Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China.
  • Yang CC; Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China.
  • Yan LJ; Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China.
  • Ding ZN; Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China.
  • Liu H; Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China.
  • Xue JS; Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China.
  • Dong ZR; Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China.
  • Chen ZQ; Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China.
  • Hong JG; Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China.
  • Wang DX; Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China.
  • Han CL; Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China.
  • Mao XC; Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China.
  • Li T; Department of Hepatobiliary Surgery, Second Hospital of Shandong University, Jinan, 250012, People's Republic of China.
Immunotherapy ; 14(18): 1481-1496, 2022 12.
Article in En | MEDLINE | ID: mdl-36537255
Immune checkpoint inhibitors (ICIs) have substantially improved the prognosis of many patients with advanced cancer. However, some patients still do not benefit from ICIs. Therefore, determining indicators that can identify patients who may benefit from ICIs is essential. As a noninvasive, convenient and inexpensive clinical indicator, the systemic immune­inflammation index is expected to solve the aforementioned issue. Through this meta-analysis, the authors demonstrated that patients with cancers with high systemic immune­inflammation index levels had shorter survival and a smaller degree of clinical benefit after ICI treatment. Moreover, a systemic immune­inflammation index value of 750 is recommended to be the cut-off value for stratifying patients.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Immune Checkpoint Inhibitors / Neoplasms Type of study: Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Immunotherapy Journal subject: ALERGIA E IMUNOLOGIA / TERAPEUTICA Year: 2022 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Immune Checkpoint Inhibitors / Neoplasms Type of study: Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Immunotherapy Journal subject: ALERGIA E IMUNOLOGIA / TERAPEUTICA Year: 2022 Type: Article